Extended-Release Naltrexone for Prisoners

• In Event: Public Health, Treatment, and Prisoner Reentry

Abstract

Research suggests that long-acting injectable naltrexone (XR-NTx) treatment may be a promising intervention for incarcerated individuals with opioid addiction histories. However, it has rarely been implemented with prison populations in the United States. Describing one of the first prison feasibility pilot studies and randomized clinical trial (RCT) in the US, this manuscript focuses on obstacles that were overcome through collaboration among prison, treatment, and research personnel. Building on the present authors’ work in developing prison-based methadone, buprenorphine, and long-acting naltrexone treatment, and considering the lack of experience in implementing prison-based long-acting naltrexone treatment programs in the US, this presentation may serve as a model for interested prison administrators, treatment providers, and researchers.

Authors

• Michael Gordon, Friends Research Institute, Inc.

• Frank Vocci, Friends Research Institute, Inc.

• Terrence T Fitzgerald, Glenwood Life Counseling Center